Enoxaparin dosing in the elderly using adjusted body weight

被引：0
作者：
Frederick Leri
Stephen J. Voyce
Salvatore Scialla
William Glavich
Edward Dzielak
Raymond A. Smego
John Guzek
机构：
[1] Moses Taylor Hospital,Department of Clinical Pharmacy
[2] Moses Taylor Hospital,Section of Cardiology
[3] Moses Taylor Hospital,Section of Hematology
[4] Moses Taylor Hospital,Section of Geriatrics
[5] The Commonwealth Medical College,undefined
来源：
Journal of Thrombosis and Thrombolysis | 2009年 / 28卷
关键词：
Enoxaparin; Adjusted dosing; Elderly; Low molecular weight heparin; Anti-Xa activity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
We prospectively compared anti-Xa activity in 61 elderly (>65 years) subjects receiving enoxaparin according to standard or adjusted body weight (ABW) dosing. In the ABW dosing group, mean patient age was 76 years, mean weight 80 kg, mean serum creatinine 1.0 mg/dl, and mean CrCl 48 ml/min. ABW dosing resulted in 57% of elderly study subjects achieving anti-Xa activity of 0.5–1.0 IU/ml, and 80% achieving anti-Xa activity of 0.5–1.2 IU/ml. Compared to standard dosing, for all subjects ABW dosing of enoxaparin was associated with a more favorable mean anti-Xa activity (0.98 IU/ml vs. 1.28 IU/ml, P = 0.001), fewer highest-risk (>1.5 IU/ml) supratherapeutic anti-Xa levels (0% vs. 28%, P = 0.001), and more frequent therapeutic levels among women (64% vs. 25%, P = 0.001). ABW dosing of enoxaparin may be beneficial in elderly patients aged 65 and older, and its benefit appears to be more pronounced in female patients.
引用
收藏
页码：348 / 353
页数：5
相关论文
共 74 条
[1]  
Yee JYV(2000)The effect of body weight on dalteparin pharmacokinetics Eur J Clin Pharmacol 6 293-297
[2]  
Duffull SB(1995)Comparison of the pharmacokinectic profiles of three low molecular mass heparins—dalteparin, enoxaparin and nadroparin—administered in healthy volunteers (doses for prevention of thromboembolism) Thromb Haemost 73 630-640
[3]  
Collignon F(2003)Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction Br J Clin Pharmacol 56 407-414
[4]  
Frydam A(2004)Heparin and low molecular weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 188S-203S
[5]  
Caplain H(2004)Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin Circulation 110 392-398
[6]  
Bruno R(2006)Meta-analysis: low molecular weight heparin and bleeding in patients with severe renal insufficiency Ann Intern Med 144 673-684
[7]  
Baille P(1999)Clinical differentiation of low molecular weight heparins Semin Thromb Hemost 25 135-144
[8]  
Retout S(2002)Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST elevation acute coronary syndromes Am Heart J 143 753-759
[9]  
Hirsch J(2007)Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level Drugs Aging 24 63-71
[10]  
Raschke R(1996)Aging and heparin-related bleeding Arch Intern Med 156 857-860
12345678